Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Preferred Shares (2016)

Historic Preferred Shares for Arrowhead Pharmaceuticals (ARWR) over the last 5 years, with Q3 2016 value amounting to $16.0.

  • Arrowhead Pharmaceuticals' Preferred Shares changed 0.0% to $16.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $16.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $16.0 for FY2016, which is 0.0% changed from last year.
  • Arrowhead Pharmaceuticals' Preferred Shares amounted to $16.0 in Q3 2016, which was down 0.0% from $16.0 recorded in Q2 2016.
  • Arrowhead Pharmaceuticals' Preferred Shares' 5-year high stood at $51.0 during Q4 2013, with a 5-year trough of $10.0 in Q2 2013.
  • Moreover, its 4-year median value for Preferred Shares was $16.0 (2015), whereas its average is $18.64.
  • Data for Arrowhead Pharmaceuticals' Preferred Shares shows a peak YoY increase of 11000.0% (in 2014) and a maximum YoY decrease of 6470.59% (in 2014) over the last 5 years.
  • Quarter analysis of 4 years shows Arrowhead Pharmaceuticals' Preferred Shares stood at $51.0 in 2013, then plummeted by 64.71% to $18.0 in 2014, then dropped by 11.11% to $16.0 in 2015, then changed by 0.0% to $16.0 in 2016.
  • Its last three reported values are $16.0 in Q3 2016, $16.0 for Q2 2016, and $16.0 during Q1 2016.